SCHEMBL684065

SCHEMBL684065

Cc1ccccc1N1CCN(Cn2c(=O)c3c(ncn3C)n(C)c2=O)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.52
ADORA2B P29275 7/20 0.48
KMT2A Q03164 1/20 0.47
GLA P06280 1/20 0.47
BLM P54132 1/20 0.47
MAPK1 P28482 1/20 0.46
HTR7 P34969 1/20 0.46
TNF P01375 2/20 0.45
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
ACHE P22303 1/20 0.44
PDE4A P27815 1/20 0.44
PMP22 Q01453 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683696 0.92 HTR2A (0.48) HTR2AADORA2BKMT2AGLABLM
SCHEMBL11156121 0.90 HTR2A (0.66) HTR2AADORA2BKMT2AHTR7TNF
SCHEMBL683646 0.89 HTR2A (0.52) HTR2AADORA2BKMT2AGLABLM
SCHEMBL683640 0.88 HTR2A (0.51) HTR2AADORA2BKMT2AGLABLM
SCHEMBL682828 0.88 ADORA2B (0.46) HTR2AADORA2BGLABLMMAPK1
SCHEMBL684376 0.88 ADORA2B (0.46) HTR2AADORA2BGLABLMMAPK1
SCHEMBL683692 0.87 L3MBTL1 (0.56) HTR2AADORA2BHTR7SMN1; SMN2
SCHEMBL684023 0.86 HTR2A (0.58) HTR2AADORA2BKMT2AGLABLM
SCHEMBL684062 0.83 HTR2A (0.52) HTR2AADORA2BKMT2AGLABLM
SCHEMBL682830 0.83 ADORA2B (0.50) HTR2AADORA2BGLABLMHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF HTR2A 1201/4885ADORA2B 786/4885KMT2A 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.